The public drugs production in the context of the COVID-19 pandemic in Brazil

• Autor(a) principal: Teixeira Pinto Ferreira Neto, Paula
• Data de Publicação: 2020
• Outros Autores: Rocha da Cunha , Camila
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Gestão & Saúde (Brasília)
• Texto Completo: https://periodicos.unb.br/index.php/rgs/article/view/32291
• topic: Produção de Produtos. Pesquisa. Laboratório Oficial.; Producción de Productos. Investigación. Laboratorio Oficial.; Production of Products. Research. Official Laboratory.

The Brazilian Unified Health System (SUS) was created in the bases of the Federal Constitute by 1988, which provided SUS participation in the drugs production and in the promotion of a scientific and tecnological development and health innovation. The public drugs production by the official laboratories and its challenges during the Covid-19 pandemic are discussed in this essey, with a focus on the drugs tested by Solidarity survey. There are 20 official laboratories in Brazil, which are responsible for 289 approved drugs, 169 active ingredients, showed in different phamaceutical forms. Moreover, 86 current Partnerships for Productive Development which are under development process and tecnology transfer of 55 drugs. In the last years, several policies were evolved in Brazil have promoted the development and the estrategic drug production for the population health. This fact reduced the production and tecnological dependence and contributed for the reduction of the SUS vulnerability. However, public laboratories with inadequate infrasctruture and lack of technical and management competence and external dependence on pharmaceutical inputs, added to a fiscal austerity policies, make the country fragile to face the pandemic.